SANUWAVE is pleased to announce preliminary revenues of $5.7 million to $5.9 million for the first quarter ended March 31, 2024. This represents the highest Q1 revenues in company history. Q1 2024 revenue increased between 51% and 56% compared to Q1 2023. UltraMist revenues for Q1 2024 increased by more than 55% versus Q1 2023 and accounted for approximately 95% of the Company's total revenues. UltraMist applicator sales were an all time quarterly record and exceeded 65% of total revenues. EDEN PRAIRIE, MN, April 10, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – SANUWAVE Health, Inc. (the "Company" or "SANUWAVE") (OTCQB:SNWV), a leading provider of next-generation FDA-approved wound care products, today announced that revenues for the first quarter of 2024 are expected to be in the range of $5.7 to $5.9 million, an increase of 51% to 56% over Q1 2023 and consistent with the high end of the range of guidance given in the Company's Q4 2023 earnings release from March 22, 2024. "As with much of the medical device and wound care industry, ...